EFFECT OF VITAMIN K2 ON COVID-19 S1 PROTEIN-INDUCED CYTOTOXICITY AGAINST HUVECS AND ON THE ACTION OF ASCIMINIB IN ABELSON-TYROSINE-KINASE-INHIBITOR-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA CELLS

EHA Library, Seiichi Okabe, 386490

POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB

EHA Library, Jorge Cortes, 386491

MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL

EHA Library, Massimo Breccia, 386492

REAL-WORLD ANALYSIS OF MUTATION CHARACTERISTICS AND CLINICAL OUTCOMES IN 343 CHRONIC MYELOID LEUKEMIA PATIENTS WITH BCR::ABL KINASE DOMAIN MUTATIONS

EHA Library, Shiwei Hu, 386493

RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY

EHA Library, Tim Hughes, 386494

1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY.

EHA Library, weiming li, 386495

RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY

EHA Library, Carlo Gambacorti-Passerini, 386496

CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING

EHA Library, Fabian Lang, 386497

ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE

EHA Library, Lukas Semerad, 386498

EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA

EHA Library, Martin Mueller, 386499

USE OF RT-QPCR VERSUS DIGITAL DROPLET PCR AND EVALUATION OF CD26+ CELLS IN LONG TFR PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Laura De Fazio, 386500

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES

EHA Library, Fadi Haddad, 386501

ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.

EHA Library, Elena Kuzmina, 386502

2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL

EHA Library, Philipp Le Coutre, 386503

IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY

EHA Library, Lucy Pemberton, 386504

UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Erica Brivio, 386505

THE FACTORS OF LATE MOLECULAR RELAPSES AFTER TYROSINE KINASE INHIBITORS DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Anna Petrova, 386506

EARLY WARNING RESPONSES IN CML PATIENTS: A REAL-LIFE TURIN EXPERIENCE

EHA Library, Valentina Giai, 386507

SPOTLIGHT ON THE REAL-WORLD TREATMENT OF CML PTS IN GERMANY: A RETROSPECTIVE SURVEY IN PRIVATE ONCOLOGY PRACTICES

EHA Library, Georg-Nikolaus Franke, 386508

PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Valentin Garcia Gutierrez, 386509

MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA

EHA Library, Ehab Atallah, 386510

THE RESULTS OF THE RUSSIAN PROSPECTIVE STUDY OF REDUCTION AND DISCONTINUATION TREATMENT OF TKI (READIT-2020) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE

EHA Library, Margarita Gurianova, 386511

TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES

EHA Library, Helen Collins, 386512

A MULTICENTER RETROSPECTIVE STUDY IN CHINA: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH CML-CP TREATED WITH DIFFERENT TYROSINE KINASE INHIBITORS

EHA Library, JIAN HUANG, 386513

LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA.

EHA Library, Chethan R, 386514

REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION

EHA Library, Massimo Breccia, 386515

EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA

EHA Library, Aram Bidikian, 386516

ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)

EHA Library, Ehab Atallah, 386517

CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?

EHA Library, Claudia Haferlach, 386518

IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172

EHA Library, Maki Sakuma, 386519

MULTIOMIC SINGLE-CELL APPROACH REVEALED CLONAL ARCHITECTURE OF KIT MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS WITH/WITHOUT SYSTEMIC MASTOCYTOSIS

EHA Library, Yu-Hung Wang, 386520

THE KEAP1-NRF2 REDOX PATHWAY IS OF CENTRAL IMPORTANCE DURING 5-AZACYTIDINE THERAPY AND THE DEVELOPMENT OF RESISTANCE VIA A SPECIFIC SET OF PROTEIN OXIDATIVE MODIFICATIONS

EHA Library, Kristýna Pimková, 386521

RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?

EHA Library, Gregor Hoermann, 386523

SINGLE-CELL MULTIOMICS ANALYSIS OF MYELODYSPLASTIC SYNDROME PREDICTS CLINICAL RESPONSE TO TREATMENT WITH DNA DEMETHYLATION AGENT

EHA Library, Ignacio Campillo-Marcos, 386524

DYNAMICS OF CLONAL EVOLUTION IN CHRONIC MYELOMONOCYTIC LEUKEMIA WITH PROGRESSION TO SECONDARY ACUTE MYELOID LEUKEMIA: PAIRED-SAMPLE COMPARISON

EHA Library, Hsiao-Wen Kao, 386525

DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY

EHA Library, Amit Verma, 386526

CRISPR/CAS9 GENE EDITING IN HEMATOPOIETIC STEM CELLS TO MODEL CLONAL COMPETITION IN VIVO AND IN VITRO FOR GATA2 DEFICIENCY

EHA Library, Damia Romero-Moya, 386527

MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)

EHA Library, Lisa Johnson, 386528

THE MECHANISM OF SETD2 IN MESENCHYMAL STEM CELLS REGULATED UBA5 IN MDS ERYTHROID DIFFERENTIATION

EHA Library, Roujia Wang, 386529

SYSTEMATIC ANALYSIS OF T LYMPHOCYTES IN MYELOID NEOPLASMS

EHA Library, Ioannis Kotsianidis, 386530

APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)

EHA Library, Irene Zamanillo, 386531

THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS

EHA Library, Adrian Mosquera-Orgueira, 386532

ABERRANT IMMUNE MICROENVIRONMENT IN BONE MARROW OF MYELODYSPLASTIC SYNDROME PATIENTS DRIVES A SUPPRESSIVE PHENOTYPE

EHA Library, Richa Rai, 386533

AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX

EHA Library, Amanpreet Bains, 386534

RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME

EHA Library, Ioannis Kotsianidis, 386535

MUTATIONS IN THE COHESIN GENE STAG2 ARE ASSOCIATED WITH REDUCED INFLAMMATORY GENEEXPRESSION AND AN INCREASE IN HEMATOPOIETIC STEM CELL POPULATIONS IN MYELODYSPLASTICSYNDROME PATIENTS

EHA Library, Shubhra Ashish Bhattacharya, 386536

HIGH MUTATIONAL CONCORDANCE IN PAIRED BONE MARROW AND PERIPHERAL BLOOD SAMPLES IN PATIENTS WITH CONFIRMED OR SUSPECTED MYELODYSPLASTIC NEOPLASM

EHA Library, Natalie Wossidlo, 386537

H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Moritz Binder, 386538

MONOCYTES MEDIATE NK CELL FUNCTION EXHAUSTION IN MDS PATIENTS VIA CD200/CD200R PATHWAY

EHA Library, Yixuan Guo, 386539

THE PREVALENCE OF FOXP3-E2 ISOFORM IN REGULATORY T CELLS CORRELATES WITH THE DEGREE OF DYSPLASIA IN MYELODYSPLASTIC SYNDROMES

EHA Library, Stefania Leone, 386540

SOLUBLE PD-L1 PREDICT POOR OVERALL SURVIVAL AND DISEASE PROGRESSION IN PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME

EHA Library, Xingcheng Yang, 386541

EXPLORING CLONAL COMPETITION THROUGH 12-YEAR FOLLOW-UP OF AN MDS-RS PATIENT WITH DUAL SF3B1 MUTATIONS

EHA Library, Pedro Moura, 386542

DISSECTING THE CLINICAL HETEROGENEITY OF ISOLATED TRISOMY 8 MYELODYSPLASTIC SYNDROMES THROUGH MUTATIONAL PROFILE

EHA Library, Sofía María Toribio Castelló, 386543

TOX REGULATED CD8+ T LYMPHOCYTES EXHAUSTED IN MYELODYSPLASTIC SYNDROMES PATIENTS THROUGH ACTIVATING AKT/PI3K/MTOR PATHWAY

EHA Library, Huaquan Wang, 386544

GENE EXPRESSION ANALYSIS REVEALS UNIQUE CHARACTERISTICS OF BONE MARROW MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS

EHA Library, WANSHU CHEN, 386545

AG946, A PYRUVATE KINASE (PK) ACTIVATOR IMPROVES PK PROPERTIES AND RED BLOOD CELL (RBC) METABOLISM UPON EX VIVO TREATMENT OF RBCS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Jonathan de Wilde, 386546

EPIGENOME PROFILING REVEALS ABERRANT DNA METHYLATION SIGNATURE IN GATA2 DEFICIENCY

EHA Library, Alessandra Giorgetti, 386547

RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

EHA Library, Guillermo Garcia-Manero, 386548

A BONE MARROW MICROENVIRONMENTAL CELL SIGNATURE SCORING SYSTEM INDEPENDENTLY PREDICTED SURVIVAL AND DRUG RESISTANCE IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS

EHA Library, Yu-Hung Wang, 386549

VALIDATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION

EHA Library, Wan Hsuan Lee, 386550

CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE

EHA Library, Aref Al-Kali, 386551

CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX

EHA Library, Alexandre Bazinet, 386552

UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME

EHA Library, Courtney DiNardo, 386553

BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY

EHA Library, Felicitas Schulz, 386554

TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA

EHA Library, Yu-Hung Wang, 386555

REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS

EHA Library, Luis E. Aguirre, 386556

EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS

EHA Library, Samuel Urrutia, 386557

LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS

EHA Library, Rashmi Kanagal-Shamanna, 386558

EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE

EHA Library, Kelly Chien, 386559

SURVIVAL IN LOWER-RISK MDS PATIENTS FROM EUMDS REGISTRY BY TWO TRANSPLANT SELECTION CRITERIA - IMPLICATIONS FOR TRANSPLANT DECISION

EHA Library, Aleksandar Savic, 386560

ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS

EHA Library, Mikkael A. Sekeres, 386561

CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE

EHA Library, Aref Al-Kali, 386563

EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES

EHA Library, Michael Robert Savona, 386564

ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS

EHA Library, Alexandre Bazinet, 386565

LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL

EHA Library, David Ross, 386566

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE COHORT MATCHED STUDY

EHA Library, Polina Kotselyabina, 386567

INCREASED FOXO1 EXPRESSION IS ASSOCIATED WITH BETTER PROGNOSIS IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING DECITABINE THERAPY

EHA Library, Zheng Zhang, 386568

PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

EHA Library, Akhil Kumar, 386569

PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

EHA Library, Amer M. Zeidan, 386570

THE VALUE OF S100A8 AND S100A9 FOR DIAGNOSIS AND PROGNOSTIC PREDICTION IN MYELODYSPLASTIC NEOPLASMS

EHA Library, Yu Wu, 386571

CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS

EHA Library, Samuel Urrutia, 386572

A REAL-WORLD STUDY OF MULTIPLE-CYCLE HYPOMETHYLATING AGENTS MONOTHERAPY IN MYELODYSPLASTIC SYNDROMES

EHA Library, Xiaozhen Liu, 386573

MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS

EHA Library, Jan Bewersdorf, 386574

REAL-WORLD ANALYSIS OF A LARGE ELECTRONIC MEDICAL RECORD DATABASE OF PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): TREATMENT PROFILES, CLINICAL EFFECTIVENESS, AND KEY ADVERSE EVENTS

EHA Library, Mellissa Williamson, 386575

CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE

EHA Library, Muhamad Oum, 386576

IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE

EHA Library, Samuel Urrutia, 386577

THE ROLE OF INCREASED IRF1 EXPRESSION OF NATURAL KILLER CELLS IN THE IMMUNE PATHOGENESIS OF SEVERE APLASTIC ANAEMIA

EHA Library, Liu zixuan, 386578

A ZEBRAFISH MODEL FOR JAGN1-ASSOCIATED SEVERE CONGENITAL NEUTROPENIA

EHA Library, Larissa Doll, 386579

UNRAVELING THE DIFFERENT PATHOMECHANISMS OF CONGENITAL AND CYCLIC NEUTROPENIAS: CYCLIC EXPRESSION OF HEMATOPOIETIC STEM-CELL-SPECIFIC TRANSCRIPTION FACTORS IN CYCLIC NEUTROPENIA

EHA Library, Karl Alexander Zeidler, 386580

TRANSCRIPTOMIC ANALYSIS OF MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS) IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA (CIN)

EHA Library, Nikoleta Bizymi, 386581

TARGETING IL-2-INDUCIBLE T CELL KINASE (ITK) TO BLOCK T LYMPHOCYTE ACTIVATION FOR THE TREATMENT OF APLASTIC ANEMIA MURINE MODEL

EHA Library, Weiwang Li, 386582

PRIME EDITING AS A NOVEL TOOL FOR PRECISE CORRECTION OF CAUSAL MUTATIONS IN FANCONI ANAEMIA GROUP A PATIENT-DERIVED CELLS

EHA Library, Lucie Peterkova, 386583

STUDIES OF THE SPECIFIC TCIRG1 MUTATIONS CAUSING CONGENITAL NEUTROPENIA

EHA Library, Vahagn Makaryan, 386584

IMPAIRED MITOCHONDRIAL FUNCTION AND MARROW FAILURE IN PATIENTS CARRYING A MUTATION ON  SRSF4 GENE

EHA Library, Maurizio Miano, 386585

INCIDENCE RATES OF HEALTHCARE RESOURCE UTILIZATION AND HEMOGLOBIN LEVELS DURING OPERA: A REAL-WORLD STUDY OF PEGCETACOPLAN TREATMENT IN US ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Jesse Fishman, 386586

THE MECHANISM OF ABNORMAL EXPRESSION AND MUTATION OF RBPJ GENE PROMOTING CLONE PROLIFERATION BY REGULATING PAF1 IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Junshu Wu, 386587

LANDSCAPE OF BONE MARROW T CELLS IN ACQUIRED APLASTIC ANAEMIA REVEALS AN ACTIVATED STATE AND A POTENTIAL CLONAL EXPANSION

EHA Library, Yan Liu, 386588

EXOSOMES FROM GRANULOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS ALLEVIATE MURINE IMMUNE-MEDIATED BONE MARROW FAILURE

EHA Library, Ash Lee Manley, 386589

PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA

EHA Library, Marie Scully, 388005

HYPERCOAGULABILITY BIOMARKERS AND THROMBIN GENERATION (TG) PREDICT VENOUS THROMBOEMBOLISM (VTE) IN METASTATIC LUNG CANCER PATIENTS

EHA Library, Patricia Gomez Rosas, 388006